National Institute of Health Grant Application


 

TIDMHML 
 
RNS Number : 7065W 
Henderson Morley PLC 
03 August 2009 
 
03 August 2009 
 
HENDERSON MORLEY PLC 
(AIM: HML) 
("Henderson Morley" "HM" or "the Company") 
 
National Institute of Health Grant Application 
 
The Board of Henderson Morley, the AIM quoted biotechnology company, is pleased 
to update the market on previous announcements regarding the Company's 
Collaborative Research Agreement with the Australian Centre for Vaccine 
Development ("ACVD"), and the submission of a grant application to the US 
government funded National Institute of Health ("NIH"). 
 
The grant application has now been submitted with the goal of securing 
non-dilutive funding to further develop the Cytomegalovirus ("CMV") Vaccine 
candidate (part of the PREPS and L-particles vaccine platform). The development 
of a vaccine for CMV is a priority for the NIH and has been identified as a 
pathogen that has a significant impact on public health. 
 
Prof Rajiv Khanna, of the ACVD is leading the Australian research, and stated: 
 "Henderson Morley's technology, and the vaccine design expertise of the 
Queensland Institute of Medical Research (QIMR), Australia, constitutes a unique 
and powerful approach to the development of a vaccine for CMV. The Poly-L 
particle approach, patented by Henderson Morley, is unparalleled in the United 
States. 
 
The HM/QIMR approach circumvents the confounding factors that have prevented a 
functional vaccine in the past. The impact of a successful vaccine would be the 
prevention of thousands of CMV infections in newborn and immunocompromised 
patients, and could save millions of dollars in hospitalization costs for the 
treatment of this deadly and evasive pathogen" 
 
Andrew Knight, Executive Chairman, commented: 
"We are of course very pleased to be working on this project with the QIMR, 
which is the largest Medical Research Institute in Australia. The Institute is 
recognized for world-class research in various areas including immunology, 
infectious diseases cancer research, genetics and epidemiology." 
 
 
=-END-- 
 
 
ENQUIRIES: 
 
HENDERSON MORLEY PLC                                    0121 442 4600 
Andrew Knight, Chairman 
 
BISHOPSGATE COMMUNICATIONS LTD                  0207 562 3350 
(Public Relations) 
Maxine Barnes 
 Gemma O'Hara 
 
BREWIN DOLPHIN INVESTMENT BANKING                    0113 241 0126 
(Nominated Adviser) 
Neil Baldwin 
 
RIVINGTON STREET CORPORATE FINANCE LTD            020 7562 3380 
(Broker) 
Monisha Varadan 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RAPBUGDRUXXGGCB

Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024